Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology
|
|
- Ada Christine O’Brien’
- 5 years ago
- Views:
Transcription
1 Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology
2 2013: Breakthrough of the Year December 20, 2013
3 Why immunotherapy? Immune system can eradicate tumor cells Adaptability Specificity Memory
4 Rationale for developing immunotherapy as treatment for cancer patients Expression of tumor antigens that can be recognized by T cells Mutations ( drivers and passengers ) that occur during tumor development/progression represent antigens that can be recognized by the immune system Association of tumor infiltrating lymphocytes (TILs) with good prognosis
5 Somatic Mutations in Different Cancers Lawrence et al, Nature, 2013
6 Immunotherapy Strategies Cytokines Adoptive cellular immunotherapy Leukapheresis of T cells stimulated in vitro Modified T cells (chimeric antigen receptors [CAR] T cells) Oncolytic viruses Vaccines Immune checkpoint blockade
7 Cancer Vaccines
8 Activate the immune system Cancer vaccines Generate specific and targeted immune responses Types: Autologous dendritic cell-based Vector-based Whole-tumor cell
9 Arcelis Products Induce Patient-specific Memory T cells Arcelis Process Final Product* In Vivo Tumor Cells or Pathogen Monocytes RNA-loaded Dendritic Cell Amplified mrna Synthetic CD40L RNA Proprietary Dendritic Cell IL-12 secretion Naïve CD8 + T cell CD8 + CD28 + Memory T cell * Delivered by intradermal injection
10 Phase 3 ADAPT Trial Design 450 newly diagnosed, intermediate and poor risk mrcc patients Open label, first-line treatment Similar design as phase 2 combination trial with key enhancements AGS-003 dosing continues through initial progression Intermediate and poor risk patients with 1-4 risk factors (phase 3 patient population is currently ~70% intermediate risk) Primary endpoint ~6 month OS improvement (.708 hazard ratio) Granted SPA by FDA and received Fast Track designation Arm A: AGS Sunitinib Therapy 1 dose every 3 weeks x 5 Followed by quarterly dosing Diagnosis, Nephrectomy, Screening Randomization (2:1); Leukapheresis (Arm A only) Arm B: Sunitinib.
11 IMA901 Composition 10 tumor-associated peptides TUMAP ID Name Function / Comments HLA-A*02 TUMAPs ADF-001 Adipose differentiation-related protein Overexpressed in several cancers; established as a ADF-002 marker for clear-cell RCC APO-001 Apolipoprotein L,1 Overexpression in RCC CCN-001 Cyclin D1 Cell cycle regulation; frequently upregulated in many cancer types GUC-001 Guanylate cyclase 1 cgmp synthesis; pro-angiogenic effects in tumors K Prune homolog 2 MET-001 Met proto-oncogene MUC-001 Mucin 1 RGS-001 Regulator of G-protein signalling 5 HLA-DR TUMAPs MMP-001 Matrix metallopeptidase 7 (matrilysin, uterine) Largely uncharacterized so far; overexpression in RCC Proliferation, motility, adhesion, invasion; various implications in malignant transformation and invasiveness of tumor cells. Well-established TAA in CRC, unmasking of epitope due to altered glycosylation in tumors Regulation of cell signalling; overexpression during revascularization in tumors Tissue remodelling, inhibition of apoptosis Walter, et al. Nature Medicine, 2012
12 Phase III Trial of IMA901 in mrcc Cyclophosphamide (300 mg/m 2 as single infusion) Sunitinib (1 cycle) R 3:2 IMA901 plus GM-CSF (i.d.) Sunitinib Sunitinib until progression or toxicity Sunitinib Stratification: Vaccination Phase 4 months Risk group (low vs intermediate) 10 IMA901/GM-CSF vaccinations Region (WEE vs. CEE vs. US vs. Asia) Nephrectomy (yes vs. no) Follow-up for PFS Every 12 weeks Max. 19 months Follow-up for OS Every 3 months Up to 8 years N=339 (last patient randomized in Dec 2012) 1st line metastatic and/or locally advanced RCC HLA-A*02-positive Documented tumor lesions Favorable or intermediate risk (Heng et al., 2009) Primary: OS Secondary: OS in biomarker subgroup, PFS safety, immune responses, novel biomarkers.
13 Immune Checkpoint Blockade Therapy
14 The Cancer-Immunity Cycle Cancer antigen release Antigen presentation Priming and activation of T cells Trafficking of T cells into tumors Recognition of cancer cells by T cells Killing of cancer cells Chen and Mellman, Immunity, 2013
15 CTLA-4 Immunologic Checkpoint Michael A. Postow et al. JCO doi: /jco by American Society of Clinical Oncology
16 PD-1 Immunologic Checkpoint Michael A. Postow et al. JCO doi: /jco by American Society of Clinical Oncology
17 Immune Checkpoint Blockade Therapy Tumor Killing +
18 Immune Checkpoint Blockade Therapy Tumor Killing
19 Immune Checkpoint Blockade Therapy Tumor Killing +++
20 % Survival Standard Survival Curve Control Standard (or Other Therapy) Time
21 % Survival Improving Survival with Immunotherapy Immunotherapy (e.g. immune checkpoint inhibitor) Control Standard (or Other Therapy) Time
22 % Survival Improving Survival with Combination Therapy Combination of immune checkpoints Immunotherapy (e.g. immune checkpoint inhibitor) Control Standard (or Other Therapy) Time
23 Targeted Immunotherapy Agents Gangadhar T et al. Nature Reviews Clinical Oncology, 2014
24 Phase II Trial of Ipilimumab in mrcc Phase II, open labeled study in patients with mrcc: Group 1: ipi 3mg/kg 1mg/kg x3: PR-1/21 (lasted 18 months) Group 2: ipi 3mg/kg 3mg/kg x3: PR-5/40 (7-21 months) Yang et al. J Immunotherapy, 2007
25 Single-agent Nivolumab (PD-1 inhibitor) in mrcc Abstract # 5009 MOTZER et al. Abstract # 5012 CHOUEIRI et al. Design Randomized, dose-ranging phase II (N=168) Biomarker-based randomized clinical trial (N=91) (Baseline and on-therapy fresh tumor biopsies) Dose IV Q3W 0.3mg/kg n =60 2 mg/kg n=54 10 mg/kg n=54 0.3mg/kg n =22 2 mg/kg n=22 10 mg/kg n=23 10 mg/kg n=24 (naïve) Prior Tx 70% 2 prior therapies No treatment-naïve pts 74% (1-3) prior therapies 24 (16%) treatment-naïve pts ORR (%) 20% 22% 20% 9% 23% 22% 13% mpfs (m) 1º endpoint PFS at 24 weeks: 36% mos (m) Not Reported G3/4 TOX 5% 17% 13% 18% Biomarker None reported Increased T-cell tumor infiltrates after nivolumab Increased serum CXCL9 and CXCL10 post-nivolumab Numerically higher (22% vs. 8%) ORR in PD-L1 (+) pts Perspective Median PFS is not impressive: Axitinib/everolimus: ~5 m (post TKI) mpfs :an appropriate endpoint? Median OS is impressive: AXIS/RECORD-1: ~20/15 m What is the best biomarker for response?
26 Phase I Nivolumab-based combination studies Arm S Sunitinib 50 mg (4/2) + nivolumab 2mg/kg Q3W (N2) or 5mg/kg Q3W (N5) Abstract # 5010 AMIN et al. (nivo + VEGF TKI) Arm P Pazopanib 800 mg QD + nivolumab 2mg/kg Q3W (N2) (N3+I1) Nivolumab 3mg/kg + ipilimumab 1mg/kg Q3Wx4 Abstract # 4504 HAMMERS et al. (nivo + ipi) (N1+I3) Nivolumab 1mg/kg + ipilimumab 3mg/kg Q3Wx4 Prior therapy 42% 100% 80% Number of patients MSKCC risk Favorable/Intermediate (94%) Favorable/Intermediate (100%) ORR (%) 52% 45% 43% 48% Median DOR range (wks) NR Median PFS (wks) ~estimated (mo) 48.9 ~ ~ ~ ~8.9 Gr. 3/4 Toxicity (%) 81.8% 70% 29% (9.5% d/cd) 61% (26% d/cd) ALT elevation 18% Hypertension 18% Hyponatremia 15% 4 DLTs (stopped) (LFTs n=3, 20%) ALT elevation 0% Diarrhea 5% Fatigue 0% ALT elevation 26% Diarrhea 13% Fatigue 8%
27 PD-L1 (+) tumor by IHC in RCC and outcome Topalian et al.* (NEJM 2012) Cho et al. (ASCO 2013) Choueiri et al. (ASCO 2014) Drug Nivolumab MPDL3280A Nivolumab ORR PD-L1 (+) 36% 20% 22% ORR PD-L1 (-) 0 10% 8% Antibody 5H1 Genentech/Roche Ab 28.8 Cell stained Tumor Immune Cell Tumor Criteria for positivity >5% Any >5% * 5/42 tested tumors were RCC
28 Results of PD-1 and PD-L1 inhibitors in mrcc and ongoing randomized trials Agent Nivolumab MPDL3280A Avelumab Ph 1 Monotherapy (n=34); RR 29% Monotherapy (n=91); RR 9-23% + Ipilimumab (n=44) RR 43% (N3/11) RR 48% (N1/13) + Sunitinib or pazopanib (n=53) RR 43-48% Monotherapy (n=69) RR 15% + Bevacizumab (n=10) RR 40% + Axitinib Ph II Monotherapy (n=168); RR 20-22% PFS mo OS mo MPDL + Bev vs MPDL vs sunitinib in treatment-naïve (NCT ) Ph III Nivolumab vs everolimus with prior VEGFR- TKI treatment (NCT Nivolumab + Ipilimumab vs Sunitinib in treatment-naïve (NCT )
29 Randomization Phase III Trial of Nivolumab vs. Everolimus Screening Treatment Follow Up Advanced or metastatic clear cell renal carcinoma progression on or after most recent therapy and within 6 months of study enrollment A B Nivolumab 3 mg/kg IV Q2wks until disease progression* or intolerable toxicity Everolimus 10 mg PO QD until disease progression* or intolerable toxicity Tumor assessments q8 weeks from randomization for 1 year then q12 weeks 2 Follow-up visits: Labs AE Assessments PK Tumor assessments continue for subjects without documented disease progression Survival Follow-up visit: Q 3 months
30 A Phase 3, Randomized, Open-label Study of Nivolumab plus Ipilimumab vs. Sunitinib in Subjects with Previously Untreated, Advanced or Metastatic Clear-cell RCC
31 Pre-surgical Combination Trial in mrcc: Nivolumab +/- Bevacizumab or Ipilimumab Arm A: Nivolumab 4 wks A PD CB Off study B Cytoreductive surgery C 4-6 wks Nivolumab 3mg/kg Q2wk Metastatic clear cell RCC Screen for eligibility R Arm B: Nivolumab + Bevacizumab 4 wks PD CB Off study Cytoreductive surgery 4-6 wks Nivolumab 3mg/kg Q2wk Arm C: Nivolumab + Ipilimumab 4 wks PD CB Off study Cytoreductive surgery 4-6 wks Nivolumab 3mg/kg Q2wk PI: Padmanee Sharma, MD, PhD
32 Immune Related Toxicities Pneumonitis Shortness of breath Enterocolitis Diarrhea, abdominal pain Hepatitis Fatigue, abdominal pain Hypophysitis Headache, vision change, fatigue, low blood pressure Dermatitis Rash Endocrine Adrenal insufficiency, hypothyroidism, diabetes mellitus
33 Case Study 1: Nivolumab - PP Baseline
34 Case Study 1: Nivolumab - PP Baseline Continues to respond > 2 years w/o toxicity
35 Case Study 2: Nivolumab - AA Baseline
36 Baseline 8 weeks
37 8 weeks Baseline 21 weeks
38 Case Study 3: Nivolumab - RD
39 Baseline
40 Baseline 16 weeks
41 2 years Baseline 16 weeks
42 Immune Checkpoint Blockade: Clinical considerations and ongoing questions Patterns of disease response: irrc Immune related AEs Optimization of dose, schedule, treatment duration Biomarkers associated with disease outcome Optimal combinatorial approaches Rechallenge (Boost)
43 Conclusions Immunotherapy is witnessing a renaissance The promise of immunotherapy and precision oncology are here Challenges: Biomarkers of response Mechanisms of resistance Overcoming toxicity Ongoing and future trials will address these challenges
44 Immunotherapy (IMT) Platform James Allison Padmanee Sharma Patrick Hwu Jorge Blando Acknowledgements PATIENTS GU Medical Oncology Eric Jonasch Jianjun Gao Sumit Subudhi Christopher Logothetis Urology Christopher Wood Jose Karam Surena Matin Radiology Chaan Ng Pathology Pheroze Tamboli Priya Rao Kanishka Sircar
Renal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationNivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial
Nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mrcc): Results of a phase I trial H. Hammers, E.R. Plimack, J.R. Infante, M.S. Ernstoff, B. Rini, D.F. McDermott, A. Razak,
More informationFifteenth International Kidney Cancer Symposium November 4-5, 2016 Marriott Miami Biscayne Bay, Miami, Florida, USA
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationInmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea
Inmunoterapia en cáncer renal metastásico: redefiniendo el tratamiento de segunda línea Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre I + 12
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationThe Really Important Questions Current Immunotherapy Trials are Not Answering
The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationKidney Cancer Session
New Frontiers in Urologic Oncology September 12 th, 2015 Kidney Cancer Session Moderator: Philippe E. Spiess, M.D. Invited Faculty Members: Wade J. Sexton, MD Jeremiah J. Morrissey, PhD Agenda for Session
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationDISCLOSURE SLIDE. ARGOS: research funding, scientific advisory board
INTERIM ANALYSIS OF THE PHASE 3 ADAPT TRIAL EVALUATING ROCAPULDENCEL-T (AGS-003), AN INDIVIDUALIZED IMMUNOTHERAPY FOR THE TREATMENT OF NEWLY-DIAGNOSED PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationCurrent experience in immunotherapy for metastatic renal cell carcinoma
Current experience in immunotherapy for metastatic renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute FOIU, Tel Aviv, 3 July 2018 Financial and Other Disclosures Off-label use of drugs,
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationAlternativas de Futuro en Cáncer Renal Enrique Grande
Alternativas de Futuro en Cáncer Renal Enrique Grande Hospital Ramón y Cajal de Madrid The ncreasingly Challenging Field of mrcc Sorafenib (US 2005, EU 2006) 3,4 Sunitinib (US & EU 2006) 3,4 Early 1940s:
More informationCLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY FOR THE RIGHT PATIENT
Daniel Heng, MD, MPH, FRCPC @DrDanielHeng Chair GU Tumour Group, Tom Baker Cancer Centre Clinical Professor, University of Calgary CLINICAL CHALLENGES IN METASTATIC RENAL CELL CARCINOMA: THE RIGHT THERAPY
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationImmunotherapy for Renal Cell Carcinoma. James Larkin
Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech
More information6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)
Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab
More informationCheckpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health
Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationUPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA. Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA
UPDATE FROM ASCO GU FEBRUARY 2018, SAN FRANCISCO, USA Prof. David Pfister University Hospital of Cologne Germany RENAL CELL CARCINOMA DISCLAIMER Please note: The views expressed within this presentation
More informationToxicity from Checkpoint Inhibitors. James Larkin FRCP PhD
Toxicity from Checkpoint Inhibitors James Larkin FRCP PhD Disclosures Research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): BMS, Eisai, GSK, MSD, Novartis, Pfizer, Roche/Genentech
More informationNEXT GENERATION DRUGS IN KIDNEY CANCER. Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden
NEXT GENERATION DRUGS IN KIDNEY CANCER Dr Aine O Reilly Karolinska Institutet Stockholm, Sweden KIDNEY CANCER SUBTYPES Papillary Type 1 and 2 Medullary Collecting duct Chromophobe Translocation Clear cell
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationTerapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico
Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationAdvances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016
Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016
More informationRenal Cell Carcinoma: Navigating a Maze of Choices
Renal Cell Carcinoma: Navigating a Maze of Choices Sumanta Kumar Pal, M.D. Associate Professor Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationIMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS
IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role
More informationA randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care
A randomized phase 2 trial of CRLX101 in combination with bevacizumab in patients with metastatic renal cell carcinoma (mrcc) vs standard of care Martin H. Voss 1, Thomas Hutson 2, Arif Hussain 3, Ulka
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationFifteenth International Kidney Cancer Symposium
The following presentation should not be regarded as an endorsement of a particular product/drug/technique by the speaker. The presentation topics were assigned to the speakers by the scientific committee
More informationImmunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania
Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions
More informationImmunotherapy for Genitourinary Cancers. Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI
Immunotherapy for Genitourinary Cancers Douglas McNeel, MD PhD Professor of Medicine University of Wisconsin Carbone Cancer Center Madison, WI Disclosures Madison Vaccines Inc co-founder, IP, consultant
More informationMelanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1
Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND
More informationImmunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital
Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved
More informationEVIDENCE IN BRIEF OVERALL CLINICAL BENEFIT
ipilimumab aligned with patient values. Although few patients had direct experience using this combination agent, patients indicated that side effects associated with nivolumab plus ipilimumab were few
More informationNew strategies and future of target therapy in advanced kidney cancer
New strategies and future of target therapy in advanced kidney cancer VHL Gene Inactivation VHL Complex Disrupted VHL Protein HIF1-a, HIF2-a Accumulation VEGF PDGF TGF-α, CXCR4 Angiogenesis Endothelial
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationA Phase II Study of Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma Patients
A Phase II Study of With or Without Bevacizumab vs in Untreated Metastatic Renal Cell Carcinoma Patients David McDermott, 1 Michael Atkins, 2 Robert Motzer, 3 Brian Rini, 4 Bernard Escudier, 5 Lawrence
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationAtezolizumab Adjuvant Study: Medical Oncologist Perspective. Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center
Atezolizumab Adjuvant Study: Medical Oncologist Perspective Sumanta K. Pal, MD City of Hope Comprehensive Cancer Center Trial overview Key issues Outline Challenges with neoadjuvant therapy Placebo control
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationCheckpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationMedia Release. Basel, 6 th February 2018
Media Release Basel, 6 th February 2018 Phase III IMmotion151 study showed Roche's TECENTRIQ (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationIntegrating novel therapy in advanced renal cell carcinoma
Integrating novel therapy in advanced renal cell carcinoma Tian Zhang, MD Assistant Professor of Medicine GU Oncology Duke Cancer Institute March 11, 2017 Disclosures Research Funding Janssen Pfizer Consultant
More informationImmune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic
Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers
More informationIdera Pharmaceuticals
Idera Pharmaceuticals ILLUMINATE-204 Clinical Data Update December 2018 Forward Looking Statements and Other Important Cautions This presentation contains forward-looking statements within the meaning
More informationOvercoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy. Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016
Overcoming Toxicities Associated with Novel Checkpoint Inhibitor Immunotherapy Tara C. Gangadhar, MD Assistant Professor of Medicine ICI Boston 2016 Overcoming toxicity A new context for evaluating toxicity
More informationCytokines: Interferons, Interleukins and Beyond. Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center
Cytokines: Interferons, Interleukins and Beyond Michael B. Atkins, MD Georgetown-Lombardi Comprehensive Cancer Center Disclosures Advisory Boards: Bristol-Myers Squibb,Amgen, Novartis, Alkermes, Infinity,
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationSociety for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases
Society for Immunotherapy of Cancer (SITC) Immunotherapy for the Treatment of Brain Metastases Geoffrey T. Gibney, MD Georgetown-Lombardi Comprehensive Cancer Center Medstar-Georgetown University Hospital
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing
ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma
More informationCarcinoma renale. Francesco Atzori. Oncologia Medica Azienda Ospedaliero Universitaria Cagliari. Posters & Oral abstracts
Carcinoma renale Posters & Oral abstracts Francesco Atzori Oncologia Medica Azienda Ospedaliero Universitaria Cagliari Milano 3 marzo 2017 Renal Cell Cancer Track 2017 Genitourinary Cancers Symposium Poster
More informationI Kid(ney) You Not: Updates on Renal Cell Carcinoma
Disclosures I Kid(ney) You Not: Updates on Renal Cell Carcinoma Nothing to disclose Renee McAlister, PharmD, BCOP Clinical Pharmacist, GU/Melanoma Vanderbilt Ingram Cancer Center September 29, 2018 Objectives
More informationMariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL
Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationCarcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia
Carcinoma renale metastatico: cambia la pratica clinica? Camillo Porta Fondazione I.R.C.C.S. Policlinico San Matteo, Pavia New target, new agent (James Brugarolas) Atezolizumab + Bevacizumab and PD-L1
More informationImmunotherapy in Lung Cancer
Immunotherapy in Lung Cancer Jamie Poust Pharm. D., BCOP Oncology Pharmacist University of Colorado Hospital Objectives Describe the recent advances in immunotherapy for patients with lung cancer Outline
More informationAACR 2018 Investor Meeting
AACR 218 Investor Meeting April 16, 218 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationTreatment Algorithm and Therapy Management in mrcc. Manuela Schmidinger Medical University of Vienna Austria
Treatment Algorithm and Therapy Management in mrcc Manuela Schmidinger Medical University of Vienna Austria A Paradigm Shift in the Treatment of mrcc 1. Sunitinib 2. Sorafenib 3. Bevacizumab+IFN-alpha
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationBasics of Immuno-Oncology
Basics of Immuno-Oncology 2016. 6. 25 Kyong Hwa Park MD, PhD Oncology/Hematology Korea University Hospital Contents Immune microenvironment in cancer Immunologic therapeutics in Oncology - Cytokines -
More informationBases biológicas de la moderna inmunoterapia en el tratamiento del cáncer
Bases biológicas de la moderna inmunoterapia en el tratamiento del cáncer Luis de la Cruz Merino. Sº Oncología Médica Hospital Universitario Virgen Macarena, Sevilla (lcruz-ibis@us.es) OUTLINE i. Definitions,
More informationExploring Therapeutic Combinations with anti-ctla-4 Antibody
Exploring Therapeutic Combinations with anti-ctla-4 Antibody Padmanee Sharma, MD, PhD Associate Professor GU Medical Oncology and Immunology M. D. Anderson Cancer Center isbtc Hot Topic Symposium October
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationOverview: Immunotherapy in CNS Metastases
Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More information